Department of Psychology, University of California Los Angeles, Los Angeles, California.
Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California.
Alcohol Clin Exp Res. 2019 Oct;43(10):2038-2056. doi: 10.1111/acer.14167. Epub 2019 Aug 23.
Alcohol use disorder (AUD) is a chronic relapsing condition that represents a significant public health concern. Pharmacological treatment development for AUD is a top research priority, and many studies are being conducted to evaluate potential AUD treatments. Understanding the brain circuitry impacted by addiction is crucial for the development of efficacious pharmacological interventions. These neuroadaptations can be probed noninvasively using functional magnetic resonance neuroimaging (fMRI). fMRI may be an effective tool to identify biomarkers for AUD pharmacotherapies, evaluating changes associated with pharmacological treatment. Thus, the present qualitative review of the literature focuses on the role of fMRI as a tool for medication development for AUD. The aim of this review was to assemble research across a range of fMRI paradigms to study the effectiveness of pharmacological treatments of adult AUD. First, we present a qualitative review of fMRI AUD pharmacotherapy studies, differentiating studies based on their dosing regimen. Second, we provide recommendations for the field to improve the use of fMRI as a biomarker for AUD pharmacotherapy.
酒精使用障碍(AUD)是一种慢性复发性疾病,是一个重大的公共卫生关注点。AUD 的药物治疗开发是一个首要的研究重点,目前正在进行许多研究来评估潜在的 AUD 治疗方法。了解成瘾影响的大脑回路对于开发有效的药物干预措施至关重要。这些神经适应性可以使用功能磁共振神经影像学(fMRI)进行非侵入性探测。fMRI 可能是识别 AUD 药物治疗生物标志物的有效工具,可评估与药物治疗相关的变化。因此,本文献的定性综述重点关注 fMRI 作为 AUD 药物开发工具的作用。本综述的目的是汇集一系列 fMRI 范式的研究,以研究成人 AUD 药物治疗的效果。首先,我们对 fMRI AUD 药物治疗研究进行了定性综述,根据剂量方案对研究进行了区分。其次,我们为该领域提供了使用 fMRI 作为 AUD 药物治疗生物标志物的建议。